Pradaxa® (dabigatran) is an anticoagulant (blood thinner) manufactured by the German pharmaceutical company Boehringer Ingelheim. The FDA approved Pradaxa®for the prevention of strokes in atrial fibrillation (a-fib) patients in October 2010.
Risk of Severe Bleeding
Since its approval, Pradaxa® has been linked to thousands of adverse events and numerous fatalities due to uncontrolled bleeding, including:
Gastrointestinal (GI) bleeding
These injuries and fatalities initially spawned thousands of lawsuits. In August 2012, roughly 4,000 claims filed by Pradaxa®patients were consolidated into a multidistrict litigation (MDL). In May 2014, Boehringer Ingelheim agreed to pay $650 million to settle the 4,000 lawsuits and claims pending at the time.
The team at Blackridge LLC is pursuing claims on behalf of victims who experienced bleeding events but were left out of the first settlement.
How We Can Help
Our firm is dedicated to serving those who are wrongfully injured, and to the fair and just resolution of their claims. The lawyers at Blackridge LLC have extensive experience litigating thousands of cases involving injuries from pharmaceuticals and medical devices. We represent individuals throughout the United States who have suffered serious injuries and death as a result of poorly designed drugs and devices. Our experienced lawyers zealously pursue each and every case to ensure our clients receive their rightful compensation.
Free Confidential Case Evaluation
If you have been harmed by Pradaxa®, please complete the no obligation confidential case evaluation below. An attorney will contact you within the next business day.